31st Annual North American Cystic Fibrosis Conference

S11 - S11: CLIN: Medications, CF & the Gastrointestinal Tract

Nov 3, 2017 10:30am ‐ Nov 3, 2017 11:55am


Description

This session will provide an overview of the use of probiotics, acid suppression and pancreatic enzyme replacement therapy in cystic fibrosis. In addition, drug-induced liver injury and the management of elevated liver enzymes with commonly used cystic fibrosis medications will be discussed.

Learning Objectives:

  1. Define drug-induced liver injury, list commonly implicated agents in cystic fibrosis and discuss management of elevated liver enzymes with commonly used cystic fibrosis medications.
  2. Review use of acid suppression in cystic fibrosis, discuss indications for use and use of alternative agents, and appraise the risks vs. benefits of long-term acid suppression.
  3. Describe the pharmacology of pancreatic enzyme replacement therapy and probiotics and appraise the evidence regarding their use for the gastrointestinal manifestations of cystic fibrosis.

Symposium Chair(s):

Symposium Speaker(s):

You must be logged in and own this session in order to post comments.

Joanna Knox
11/4/17 1:58 am

Session was very good, big thanks to all the speakers. Would like to see studies as to if the adjusted ph of the intestine if it was below 5, could impact on probiotic's effectiveness.